With the recently approved ozanimod, another highly potent agent for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS) is entering the Swiss market. The oral sphingosine-1-phosphate (S1P) receptor modulator demonstrated high efficacy and a safety profile comparable to interferon β1a in two randomized multicenter phase 3 trials with a total of over 2600 participants. A large follow-up study, which included nearly 85% of patients, continues to yield promising results.
Prof. Andrew Chan, M.D., Medical Director of the Neuro Division, Chief of Medicine and Vice. Clinic Director of the Department of Neurology at the University Hospital of Bern answers questions about the efficacy, safety, tolerability and application of the new active ingredient in an interview.
